UNICEF and Gavi announce an agreement that cuts the price of the RTS,S/AS01 malaria vaccine by about 40%, with the aim of expanding childhood immunisation and reducing programme costs. The deal is reported to generate around US$50 million in savings over 2027 to 2029.
Business Line reports that Bharat Biotech also moves to slash the price of its malaria vaccine, MOSQIVAC, by 40%, describing the impact as protection for an additional 1 million children and $50 million in savings. AllAfrica frames the same broad outcome in terms of a UNICEF–Gavi-supported agreement and programme savings for childhood immunisation efforts. Across outlets, the common focus is the 40% price reduction and its expected benefits for reaching more children and lowering costs, though the emphasis differs between vaccine-specific branding and the funding/implementation partnership.
